Abstract: b-arrestin1 (or arrestin2) and b-arrestin2 (or arrestin3) are ubiquitously expressed cytosolic adaptor proteins that were originally discovered for their inhibitory role in G protein-coupled receptor (GPCR) signaling through heterotrimeric G proteins.
INTRODUCTION
G protein-coupled receptors (GPCRs) or 7-transmembrane receptors are the most diverse and well-represented group of membrane receptors, with approximately 800 members in the human genome. They recognize a variety of stimuli that include light, hormones, and chemokines and convert these signals to relevant intracellular messages. GPCR activation can significantly influence many cellular biochemical reactions, cell structure, cell motility, and gene expression. GPCR signaling regulates almost every aspect of human physiology and not surprisingly, approximately 40% of currently prescribed medications act on GPCRs either directly or indirectly. [1] [2] [3] [4] GPCRs have a conserved heptahelical architecture and interact with at least 3 families of proteins in an agonistdependent manner. These 3 families include (1) the heterotrimeric G proteins, (2) GPCR kinases or GRKs and (3) arrestins. 1, 2 The heterotrimeric G proteins are generally divided into 4 main classes based on sequence similarity of the Ga subunit: Ga s , Ga i/o , Ga q/11 , and Ga 12/13 . 5 In an activated conformation, GPCRs function as efficient guanine nucleotide exchange factors (GEFs) for bound G proteins and promote the activation of Ga and their dissociation from Gbg subunits. The activated G protein subunits in turn trigger a signal transduction cascade through various effector molecules and kinases. Seven GRKs (1-7) are expressed in human cells. 6, 7 Although GRKs 1 and 7 are confined to the retina, GRK 4 is mainly expressed in the brain, kidney, and testes, and GRKs 2, 3, 5, and 6 are expressed ubiquitously. The arrestin family includes 2 visual (arrestins 1 and 4) and 2 nonvisual, ubiquitously expressed arrestins (arrestins 2 and 3, also known as b-arrestin1 and b-arrestin2, respectively). b-arrestins 1 and 2 share ;80% amino acid sequence identity and present unique as well as redundant roles in GPCR regulation. [8] [9] [10] Ablation of both b-arrestin isoforms causes embryonic lethality in mice, whereas genetic deletion of a single isoform leads to viable offsprings in which GPCR activation engenders distinct responses, perhaps through individual b-arrestin isoforms. 7, 10 The GRKs and arrestins were initially identified as inhibitors of GPCR signaling, but their roles in GPCR signal transduction are multifactorial and continuously evolving.
GRKS AND b-ARRESTINS PROMOTE DESENSITIZATION OF GPCRS
Most agonist-activated GPCRs are rapidly uncoupled from G proteins resulting in signal desensitization by an efficient 2-step process: (1) phosphorylation by GRK(s) and (2) b-arrestin binding (Fig. 1A) . 4 Although b-arrestin binding physically obstructs G protein coupling to the GPCR, additional mechanisms are in play by which b-arrestins ensure efficient blockade of G protein signaling. b-arrestins scaffold cyclic nucleotide phosphodiesterases (PDEs) and diacylglycerol kinases (DGKs) that degrade second messengers downstream of activated receptors (Fig.  1A) . 11, 12 PDEs of the PDE4 family terminate cyclic adenosine monophosphate (cAMP) signaling by converting cAMP to AMP.
By recruiting PDE4D3 and PDE4D5 to the activated b 2 -adrenergic receptor (b 2 AR), b-arrestin2 decreases cAMP levels and cAMP-dependent protein kinase A (PKA) activity. 13 This in turn attenuates PKA-mediated b 2 AR phosphorylation, preventing the switching of b 2 AR coupling from G s to G i . 14 b-arrestin scaffolding of PDE4D is receptor specific, as constitutive binding of the PDE4D8 isoform to the b 1 AR does not require b-arrestins and PDE4D8 dissociates from the b 1 AR on agonist stimulation of the receptor. 13, 15 In addition, b-arrestin can diminish M 1 muscarinic receptor-mediated protein kinase C (PKC) activity by recruiting DGKs. 16 M 1 muscarinic receptors couple to G q/11 to stimulate phospholipase C (PLC) that catalyzes the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). b-arrestin translocation to the activated receptor leads to the recruitment of DGKs, which decrease DAG-dependent PKC activity by phosphorylating DAG, which is then converted into phosphatidic acid. 16 Phosphatidic acid not only serves as an intermediate for phospholipid synthesis, but also plays important roles in signal transduction and membrane dynamics as a second messenger. 17 Thus, although b-arrestin's partnership with PDEs can terminate second messenger signaling, barrestin's association with DGKs can initiate an additional wave of signaling through phosphatidic acid production.
BIMODAL SIGNALING OF GPCRS
Although the b-arrestins were considered as inhibitors of GPCR signaling for nearly a decade after their discovery, a large body of work that followed has changed our appreciation about the functional roles of b-arrestins. 8 
b-arrestins
have been shown to function as critical adaptors for agonistinduced endocytosis of GPCRs, 18, 19 and also as important adaptors for agonist-induced ubiquitination of GPCRs, [20] [21] [22] [23] [24] thus governing the trafficking itinerary of internalized GPCRs (Fig. 1B) . b-arrestins were shown to form signaling scaffolds for mitogen-activated protein kinases (MAPKs) such as the extracellular signal-regulated kinases 1 and 2 (ERKs) and c-Jun N-terminal kinase 3 (JNK3) on endosomes with internalized GPCRs (Fig. 1C) . 25 Subsequently, b-arrestins were shown to promote some of these pathways even when the G protein activity is disabled. 3, 26 Thus, GPCR signaling is bimodal, in which the first mode is dependent on G proteins and the second mode dependent on GRK phosphorylation of the GPCR and on b-arrestin-dependent signaling. 4, [27] [28] [29] GPCRs can be activated to favor one of these modes over the other, thus engendering biased signaling (Fig. 2) . In some cases, complete bias allows signaling through only one mode:
either G protein(s) or b-arrestin(s).
PHOSPHORYLATION BARCODING BY GRKS REGULATES b-ARRESTIN ACTIVITY
Phosphorylation of activated GPCRs by GRKs, originally described as the first step in GPCR desensitization, is now known to be a critical regulatory mechanism, which initiates a variety of downstream effects by engaging different conformations of b-arrestins and promoting their various functions. 12, [30] [31] [32] The correlation between the extent of FIGURE 1. b-arrestins act as multifunctional adaptors for activated GPCRs. A, Agonist-occupied GPCRs are rapidly phosphorylated by specific GPCR kinases on target serine(s) and threonine(s) in the intracellular domain(s) of GPCRs. The pattern(s) of phosphorylation dictates the stability and duration of b-arrestin-GPCR association. b-arrestin-binding interdicts G protein coupling and blocks G protein-mediated signaling. This results in desensitization of GPCR signaling. b-arrestins scaffold enzymes namely, PDE and DGK that degrade second messengers generated by G protein activity. This process boosts the efficiency and fidelity of b-arrestinmediated desensitization. B, b-arrestin undergoes conformational rearrangement(s) on its association with GPCRs; so activated barrestin interacts with adaptors of the endocytic machinery and with specific E3 ubiquitin ligases that ubiquitinate either b-arrestin GPCR phosphorylation and the affinity of GPCR-arrestin complex is inferred by the distinct patterns of b-arrestin recruitment dictated by the abundance and distribution of serine/threonine residues in the GPCR intracellular domains. 33, 34 A stable b-arrestin/GPCR endosomal complex is formed by GPCRs that have clustered serine/threonine motifs in their carboxyl tails (for example, the AT 1a R). In contrast, a transient plasma membrane complex is obtained with GPCRs that possess discontinuous or scattered serines/ threonines (for example, the b 2 AR). Eliminating all the phosphorylation sites by mutagenesis either weakens a former strong b-arrestin interaction (eg, AT 1a R) 35 or eradicates an original weak b-arrestin binding (eg, b 2 AR). 8 Studies conducted with a number of GPCRs (b 2 AR, 36 follicle-stimulating hormone receptor, 37 somatostatin 2A receptor, 38 thyrotropin-releasing hormone receptor, 39 dopamine D 1 receptor, 40 free fatty acid receptor 4, 41 neuropeptide FF2 receptor, 42 and other GPCRs 11, 43 ) showed that elimination of specific phosphorylation sites in a GPCR has distinct downstream effects on b-arrestin binding and/or signaling. Using mass spectrometry and phosphosite antibodies, differential phosphorylation of M3 muscarinic receptor was demonstrated in different cell and tissue types suggesting that particular patterns of phosphorylation engender tissue-specific signaling. 44 By using quantitative proteomics, chemically distinct ligands were shown to produce qualitatively similar mixture of phosphorylated m-opioid receptors (MORs). 45 However, multisite phosphorylation of a specific serine-threonine motif is required for MOR internalization as well as b-arrestin recruitment. Phosphorylation of this region is quantitatively greater when MORs are stimulated with DAMGO than when stimulated with morphine. 45 These studies support the idea that distinct phosphorylation motifs may be sensed by GRKs yielding a distinct outcome through subsequent protein interactions, especially through b-arrestin recruitment.
The differential roles of GRK isoforms in regulating a particular GPCR-activated function of b-arrestin became evident from targeted knockdown of each GRK by RNAi. 46, 47 GRK2 and/or GRK3-mediated bulk phosphorylation of the AT 1a R and of the vasopressin receptor (V 2 R) enables b-arrestin binding and internalization, but not ERK activation. In contrast, GRK5 and/or GRK6-mediated phosphorylation of the same 2 GPCRs leads to b-arrestindependent ERK activation but does not provoke robust b-arrestin binding nor internalization. The chemokine receptor CCR7 is activated by 2 endogenous agonists, namely CCL19 and CCL12, which engage different GRK isoforms and promote different downstream effects through b-arrestin. CCL19 stimulation promotes GRK3 and GRK6-mediated CCR7 phosphorylation, whereas CCL21 engages only GRK6 leading to differential consequences: b-arrestin-dependent ERK activation by both agonists and robust b-arrestin binding and desensitization only by CCL19. 48 Specific phosphorylation barcodes were delineated by mapping the GRK phosphorylation sites on activated b 2 AR and the chemokine receptor CXCR4 by employing combinatorial approaches involving stable isotope labeling, mass spectrometry, site-directed mutagenesis, site-specific phosphoantibodies, and RNAi of individual GRKs. 49, 50 These studies confirmed the presence of GRK isoform-dependent, 49 In summary, barcoding of GPCRs by GRKs that define specific activities through b-arrestins involves hierarchical molecular mechanisms (Fig. 3) . As a first tier of regulation, each GPCR has distinct phosphorylation sites or motifs distributed in its intracellular domains. As a second tier of regulation, the recruitment of a GRK is dictated by specific ligand-activated conformation(s) of the GPCR. As a third tier of fine tuning-specific b-arrestin-dependent signaling, the expression level of GRK isoforms can be modulated in a cell type or tissue, such that only certain phosphorylation codes are enabled. 51 As a fourth tier of regulation, each GRK phosphorylates a set of target sites, which can be either overlapping or nonoverlapping with other GRKs or with other serine/threonine kinases. In some cases, GRKs can compete or antagonize each other's activity suppressing or increasing specific phosphosignatures. 46 55 Interestingly, b-arrestins were shown to simultaneously bind and link components of a kinase cascade (ie, binding to MAPKKK and MAPK) and act as kinase scaffolds (Fig. 1C) . [56] [57] [58] On GPCR activation, b-arrestins also scaffold or sequester other nonkinase proteins such as small GTPases, phosphatases, or adaptor proteins, promoting the formation of various signalosomes that regulate cellular activities (Fig. 4) . Accordingly, b-arrestin's roles as a scaffold in signal transduction can be broadly classified as (1) b-arrestin scaffolding that primarily involves kinases and (2) b-arrestin scaffolding that primarily involves nonkinase proteins with or without a secondary link to a kinase activity.
b-Arrestin Scaffolding That Primarily Involves Kinases

Non-Receptor Tyrosine Kinases
Soon after the identification of b-arrestins' roles as endocytic adaptors for activated GPCRs, they were shown to trigger MAPK signaling by binding and recruiting several members of the Src family non-receptor tyrosine kinases (RTKs). 25 b-arrestin-dependent Src activity in turn regulates On AT 1a R agonist stimulation, b-arrestin2 specifically localizes activated JNK3 on endosomes, analogous to its ability to scaffold activated ERK on endosomes. 58 However, for the metabotropic glutamate 7 (mGlu7) receptor, 68 b-arrestin-mediated JNK signaling is regulated by specific GRKs and b-arrestin isoforms: GRK4 activates JNK, whereas GRK2 promotes ERK signaling; b-arrestin2 enables JNK activation, but inhibits ERK, whereas b-arrestin1 activates ERK while inhibiting JNK. 68 In addition to promoting ERK and JNK signaling, barrestins also regulate p38 MAPK activation. CXCR4-induced p38 activity promotes cellular chemotaxis and is primarily mediated by b-arrestins. 69 b 2 AR provokes biphasic p38 activation through G protein and b-arrestin-dependent mechanisms. Although the late p38 activation is G s /cAMP mediated, early p38 activation is dependent on b-arrestin1/ Rac1-GTPase/NADPH oxidase signaling and is solely responsible for agonist-induced F-actin rearrangement. 70 For the k-opioid receptors, b-arrestin-dependent signaling and p38 activation require phosphorylation of the receptors by GRK3. 71 Although the analgesic effects of kappa opioids are G protein mediated, dysphoria and addiction are linked with b-arrestin-dependent p38 activation. 72 
PI3K, Akt, and GSK3b Signaling
The activity of phosphatidylinositol-3 kinase (PI3K) is modulated by b-arrestin as well. However, although b-arrestins inhibit Ga q /Ca 2+ -dependent PI3K activation downstream of the protease-activated receptor 2 (PAR2), they facilitate PI3K activity for the chemokine receptor CCR5. 73, 74 CCR5 stimulation by the chemokine macrophage inflammatory protein-1b (MIP-1b) promotes macrophage chemotaxis by G i -dependent as well as by G i -independent/b-arrestin-dependent signaling mechanisms. The latter signaling involves concurrent activation of ERK, protein tyrosine kinase 2B (Pyk2), PI3K p85 regulatory subunit, and the tyrosine-protein kinase Lyn in a multimolecular complex that is scaffolded by b-arrestins and recruited to the activated CCR5. 74 b-arrestin induces the activation of the serine/threonine kinase Akt (also known as protein kinase B) downstream of ghrelin receptor GHS-R1a and a-thrombin receptor. 75, 76 Generally, Akt affects components of the apoptotic machinery either directly or indirectly, promotes cell survival, regulates cell proliferation, and myocardial angiogenesis. 77 b-arrestin scaffolding of GHS-R1a, c-Src, and Akt into a multiprotein complex is necessary for prolonged Akt signaling. 76 In contrast, G protein-mediated Akt activation by ghrelin involves Gbgtriggered PI3K activation, Akt phosphorylation by c-Src and subsequently by 3-phosphoinositide-dependent protein kinase 1 (PDK1), and mammalian rapamycin-insensitive complex 2 (mTORC2). 76 In the case of the thrombin receptor PAR4, formation of a heterodimer with the purinergic receptor P2Y 12 promotes sustained b-arrestin-mediated Akt activation. 78 AT 1 R stimulation also leads to b-arrestin-dependent PI3K/Akt activation which contributes to phosphorylation and inactivation of Bcl-2-associated death promoter, a proapoptotic protein of the Bcl-2 family. 79 phosphatidyl-dependent kinases PDK1 and PDK2/rictormTOR, in a PI3K-dependent manner. b-arrestin2 when recruited to the D 2 R enhances Akt and PP2A association, leading to Akt dephosphorylation and inactivation. 82 Lithium compounds used as a mood stabilizing medication inhibit GSK3b activity directly or as shown in vivo, by disrupting b-arrestin-PP2A-Akt complexes, which then promotes Akt activation and GSK3 inactivation. 83, 84 b-arrestin-mediated
Akt/PP2A/GSK3b signaling cascade presents as a target for antipsychotic drugs aimed at treating schizophrenia. 83, 84 However, b-arrestin2 does not associate with Akt downstream of PAR2, but forms a complex with PP2A/GSK3b in a Rho kinase-dependent manner. 85 b-arrestin-PP2A-GSK3b
signaling facilitates stem/progenitor cell survival in normal colon crypts and colon cancer. 85 
Transactivation of Receptor Tyrosine Kinases
GPCR-triggered transactivation of RTKs, namely epidermal growth factor receptor (EGFR), insulin-like growth factor type 1 receptor (IGF-1R), and vascular endothelial growth factor receptor (VEGFR), are modulated by both b-arrestin and G protein-dependent mechanisms (Fig. 4A) . 25, 29, 86 b-arrestin2 inhibits EGFR transactivation by CXCR7 and counteracts mitogenic signaling and cell proliferation. 87 However, b-arrestins promote sphingosine-1-phosphate-induced transactivation of fetal liver kinase 1 (Flk-1) through S1P1/S1P3 receptors, resulting in mouse embryonic stem cell proliferation. 88 b-arrestins also mediate EGFR transactivation by the b 1 AR, 89 a genetic variant of a 1 AR, 90 ET 1A R, 91 urotensin II receptor, 92 GPR39, 93 and GPR54. 94 b-arrestin-mediated EGFR transactivation may induce diverse cellular responses such as cardioprotection when provoked by b 1 AR and urotensin II receptor, cardiomyoblast hyperproliferation and hypertrophy in the case of a 1 AR, myogenesis for GPR39, and cancer cell invasiveness for ET 1A R and GPR54. [89] [90] [91] [92] [93] [94] b-arrestin2 and AT 1 R-dependent EGFR transactivation and ERK signaling are also evoked by mechanical stimuli such as membrane stretch and lead to load-induced cardiac hypertrophy. [95] [96] [97] Hearts from mice lacking either b-arrestin2 or AT 1 Rs fail to promote EGFR transactivation and ERK phosphorylation in response to mechanical stretch, while they do promote enhanced myocyte apoptosis. 97 Besides b-arrestin2, Src kinase is also required for the pathologic effects of stretch because Src inhibition prevents stretch-induced activation of ERK and significantly reduces pressure overload-induced hypertrophy and improves cardiac function. 98 AngII-induced b-arrestin2-mediated EGFR transactivation contributes to the development of aortic aneurysms, a vascular disease characterized by the dilation, degeneration, and eventual rupture of the wall of the aorta. The proaneurysmal effects of b-arrestin2 are independent of TGF-b and of AT 1a R-induced G q signaling. 99 However, AngII-induced abdominal aortic aneurysms and macrophage infiltration into the abdominal aorta are attenuated in the absence of b-arrestin2. 100 This outcome coincides with reduced expression of the inflammatory markers cyclooxygenase-2 (COX-2), monocyte chemoattractant protein-1, and macrophage inflammatory protein-1a. 100 The matrix metalloproteases forms a complex with a GEF, p115RhoGEF, 103 enabling p115RhoGEF translocation to the plasma membrane, and concomitant RhoA activation, which promotes focal adhesion remodeling and stress fiber formation. 103 Formyl-Met-LeuPhe (fMLP) receptor-triggered membrane ruffling is regulated by agonist-induced disassembly of cytosolic b-arrestinRal guanine nucleotide dissociation stimulator (RalGDS) complexes, which allows RalGDS to translocate to membrane domains and promote Ras-independent Ral signaling and Rho activation. 104 RhoA activation and stress fiber formation by the AT 1 R are dependent on both Ga q/11 and b-arrestin1. 
Wnt and b-Catenin Signaling Pathways
Wnts are secreted lipoglycoproteins that trigger signaling through the 7-transmembrane Frizzled (Fzd) receptors, which function in concert with their single transmembrane coreceptors called low density lipoprotein receptor-related protein 5/6 (Lrp5/6). Wnt signaling is essential for embryonic development; it also regulates cell adhesion, polarity, and migration and contributes to cardiac fibrosis. 112, 113 Canonical Wnt signaling involves inhibition of GSK3 downstream of Fzd-LRP5/6 and stabilization of b-catenin b-arrestin2 also associates with Dvl-2 downstream of PAR1 on binding of activated protein C to a coreceptor called endothelial protein C receptor (EPCR). 120 The binding of activated protein C with EPCR facilitates the cleavage of PAR1 at a site different from the thrombin cleavage site and stimulates PAR1 signaling. 121 Although the EPCR/ PAR1 signaling has anticoagulant and anti-inflammatory effects in endothelial cells, thrombin-induced activation of PAR1 promotes coagulation and inflammation. [122] [123] [124] barrestin2 enables activated protein C-triggered PAR1 signaling through a mechanism that involves (1) EPCR-dependent recruitment of GRK5 to the cytoplasmic domain of PAR1, (2) b-arrestin2 scaffolding of Dvl-2, and (3) induction of Rac1 signaling, which confers protection against thrombin-induced endothelial barrier permeability. 120, 125 b-arrestin1 forms 2 trimeric signaling complexes after ET A R activation to induce b-catenin signaling pathways and promote cell invasion. First, b-arrestin activates Src, leading to EGFR transactivation, MAPK signaling, and b-catenin stabilization through Tyr phosphorylation. Second, b-arrestin inhibits the "destruction complex" formed by GSK3b, Axin1, adenomatous polyposis coli (APC), and the E3 ligase b- isoforms interact with a recently identified negative regulator of Smo, the orphan GPCR, GPR161, which represses Hh signaling by constitutively activating cAMP. 136, 137 In a Smo, GRK2
and clathrin-dependent manner, b-arrestin binds to GPR161 and promotes GPR161 clearance from the cilium. 136 NF-kB through a G protein-mediated, PKCa-dependent mechanism that induces IkB kinase (IKK) phosphorylation, or through an alternative pathway in which b-arrestin2 promotes IKK activation by recruiting the adaptor protein CARD and MAGUK domain-containing protein 3 (CARMA3) (Fig.  4C) . 138 On LPAR activation, CARMA3 forms a complex with B-cell chronic lymphocytic leukemia-lymphoma 10 (Bcl10), mucosa-associated lymphoid tissue lymphoma translocation gene 1 (MALT1), and the E3 ligase tumor necrosis factor receptor (TNFR)-associated factor 6 (TRAF6) to form the CBM signalosome, which associates with IKK to ubiquitinate the regulatory subunit of the IKK complex called the NF-kB essential modulator. 138 NF-kB activation elicited by GPCRs such as AT 1a R, ET 1 R, CXCR4, and PAR1 or by RTKs such as EGFR and VEGFR2 requires CARMA3; however, NF-kB activated by cytokine receptors such as the TNFR is not dependent on CARMA3. 138 b-arrestin2, and not b-arrestin1, is required for LPAR and PAR1-mediated NF-kB signaling and CARMA3-containing CBM signalosome assembly, as it recruits CARMA3 to the activated GPCR complexes (Fig. 4C) . 138 However, both b-arrestin isoforms are known to interact with TRAF6, the NFkB inhibitor IkBa, and regulatory kinases such as IKKs a and b and NFkBinducing kinase. [139] [140] [141] Interestingly, b-arrestin isoforms reciprocally regulate NFkB signaling, inflammation, and consequently atherosclerosis. For instance, b-arrestin2 promotes aortic smooth muscle cell proliferation and migration, whereas b-arrestin1 inhibits these processes. 142 Moreover, although b-arrestin1 inhibits NFkB signaling by preventing IkB degradation and TRAF6 ubiquitination downstream of TNFR and the Toll-like receptor/interleukin-1 receptor respectively, it promotes NFkB signaling in endothelin-1-stimulated epithelial ovarian cancer cells by forming a complex with the p65 subunit of NFkB. 139, 141, 143 However, b 2 AR stimulation inhibits NFkB signaling by promoting b-arrestin2 interaction with IkB. 140 b-arrestin2 effects on NF-kB signaling are closely associated with its ubiquitination status. 54 Ubiquitinated b-arrestin2 promotes NF-kB signaling in smooth muscle cells, whereas deubiquitinated b-arrestin2 attenuates NF-kB signaling by scaffolding the deubiquitinase USP20, that in turn deubiquitinates TRAF6, which blocks the NF-kB signaling cascade. 54 Although these effects of reversible b-arrestin ubiquitination are demonstrated for the Toll-like receptor pathway, these mechanisms may potentially regulate NFkB signaling downstream of GPCRs.
cAMP/Epac/CaMKII Pathway and Hypertrophic Signaling
Both b-arrestins 1 and 2 are required for b 1 AR-induced CaMKII activation (Fig. 4D) . 144 b-arrestin-mediated CaMKII activation by the b 1 AR increases cardiac excitationcontraction coupling through phosphorylation of ryanodine receptors, phospholamban, cardiac troponin I, and myosinbinding protein C and induces myocardial hypertrophy after pressure overload and chronic isoproterenol stimulation. [145] [146] [147] b-arrestins form a complex with CaMKII and the cAMP sensor protein exchange protein directly activated by cAMP 1 (Epac1), enabling their translocation to the plasma membrane on b 1 AR activation. CaMKII activation through Epac involves Rap-PLC-e-PKC-e signaling and is independent of cAMPdependent PKA. 144 Epac1 binding to cAMP activates the small GTPases of Ras superfamily Rap1 and Rap2. Epac1 also couples to H-Ras in a b-arrestin2-dependent manner, promoting H-Ras activation through Rap2B and subsequent hypertrophic signaling. 146 Prolonged G protein activity and cAMP response have been observed in early endosomes for the following GPCRs: thyroid-stimulating hormone receptor (TSHR), parathyroid hormone receptor type 1 (PTH1R), and V 2 R which couple with G s and for the sphingosine-1-phosphate receptor (S1PR) which couples to G i . [149] [150] [151] [152] [153] PTH1R and V 2 R belong to the group termed as "class B," because they have equal affinity for either b-arrestin isoform and promote stable b-arrestin interaction and sustained ERK signaling in endosomes. 148, 149 In contrast, the class A receptor b 2 AR, 34 which prefers to bind b-arrestin2, forms transient complexes with b-arrestin2 and fails to induce cAMP signaling in endosomes unless the b 2 AR is forced to have the carboxyl tail of V 2 R (b 2 V 2 R chimera). 148 For the S1PR sustained endosomal signaling after washout is ligand specific and is triggered by FTY720-phosphate but not by the native ligand S1P. 153 Similar ligand dependence is observed for the V 2 R because vasopressin, but not oxytocin, induces b-arrestin recruitment to endosomes, as well as prolonged cAMP signaling in endosomes. 150 b-arrestins, by sequestering the activated receptors away from PDEs at the cell surface or by inhibiting PDE4 activity through ERK activation in endosomes, may promote sustained cAMP production. 154, 155 Intriguingly, desensitization of vasopressin-mediated cAMP generation involves the retromer complex (VPS26/29/35) that regulates trafficking of internalized receptor from endosomes to the Golgi; of these retromer subunits, VPS26 crystal structures have shown a strong structural homology with b-arrestins. 156 Super complexes, termed as "megaplexes" consisting of the activated receptor, b-arrestin, Ga, and Gbg subunits, have been characterized by cryo-electron microscopy and bioluminescence resonance energy transfer, suggesting that G protein and b-arrestin interactions with activated GPCRs are not mutually exclusive. 148 A ternary complex containing PTH1R, b-arrestin, and the Gbg dimer was observed in endosomes in response to PTH stimulation. 152 b-arrestin is known to embrace 2 different conformations when bound to GPCRs as observed in negative-stain cryo-electron microscopy study of the b 2 V 2 R chimera. 52, 157 Of the 2 detected b-arrestin conformations, the "core" conformation involves tight interaction with the activated receptor through full integration of b-arrestin into the transmembrane core of the receptor while concurrently binding with the phosphorylated C-terminal tail of the receptor. The other conformation involves loose receptor interaction as b-arrestin "hangs" from the phosphorylated C-terminal tail of the activated receptor ("tail" conformation). 157 b-arrestin1 configuration in the megaplex of signaling endosomes assumes the "tail" conformation of the receptor complex which perhaps enables concurrent interaction of the heterotrimeric G s with the transmembrane core of the receptor for signal transduction. 148 The core interaction of b-arrestin in the b 2 V 2 R-b-arrestin complex hinders G protein coupling to the receptor but is also found to be expendable for agonistinduced receptor internalization as well as for b-arrestin binding and activation of ERK. 148, 158 Thus, the tail conformation by simultaneously enabling G protein coupling to the internal- 
GPCRs to Exosomes
Exosomes are extracellular vesicles that play an important role as intercellular messengers, influencing the cellular activities of neighboring cells through the transfer of bioactive molecules such as lipids, proteins, RNAs, and microRNAs (miRNAs). 160 Intriguingly, b-arrestin regulates the intercellular trafficking of functional GPCRs through exosomes. Mice subjected to cardiac pressure overload release functional AT 1 Rs into circulation, and these receptors are packaged into exosomes in a b-arrestin2-dependent manner. 161 Although b-arrestin2 is not required for the intracellular maturation and exocytosis of exosomes, it is necessary for the sorting and packaging of the AT 1 R and possibly other GPCRs into these vesicular bodies. The exosomes released from cardiomyocytes during cardiac pressure overload are transferred to recipient cells that include cardiomyocytes, skeletal myocytes, and mesenteric resistance vessels, and could serve as reservoirs of functional AT 1 Rs to preserve cardiovascular homeostasis. 161 
b-ARRESTIN-BIASED AGONISTS
The therapeutic potential of b-arrestin-dependent signaling has attracted tremendous research interests in academia as well as pharmaceutical companies and a number of ligands with bias for b-arrestins have been discovered and their biological properties described (Table 1) . 27, 29 The following sections include some of the well-studied GPCR examples for b-arrestin-biased agonism highlighting the biological effects and therapeutic potential of b-arrestinbiased signaling.
AT 1 R
AT 1 R and the renin-angiotensin-aldosterone system (RAAS) are targeted for renal and hypertensive vascular diseases because of their predominant role in stimulating vasoconstriction. Angiotensin receptor blockers are commonly used to alleviate hypertension, diabetic nephropathy, cardiac hypertrophy, and congestive heart failure.
An AngII analog, SII ([Sar 1 , Ile 4 , Ile 8 ]AngII) is a modified AngII peptide, which does not activate G q -dependent calcium influx and IP3 production. 162 However, SII functions as a b-arrestin-biased agonist (Fig. 2) and triggers AT 1 R phosphorylation, b-arrestin recruitment as well as b-arrestinmediated receptor internalization and signaling. Elegant phosphoproteomics studies have revealed that although AngII and SII provoke matching phosphorylation of common proteins, SII also triggers unique phosphorylation patterns (based on phosphopeptide identification). 163, 164 SII elicits GRK6 and b-arrestin2-dependent ERK activation in endosomes and promotes b-arrestin-regulated Akt activity and mTOR phosphorylation to stimulate protein synthesis. 80, 165 b-arrestin1-dependent signaling triggered by the stimulation by the b-arrestin-biased agonist SII increases circulating aldosterone levels. b-arrestin1-mediated aldosterone elevation worsens cardiac function after myocardial infarction and accelerates cardiac remodeling. Inhibition of adrenal b-arrestin1 is cardioprotective because it decreases circulating aldosterone levels and regresses remodeling of the infarcted heart. 167 b-arrestin-biased agonists of AT 1 R that have cardioprotective effects. 169 They bind AT 1 R with higher affinity than SII and antagonize AngII-stimulated G protein signaling. Binding of these peptide ligands to the AT 1a R also promotes b-arrestin recruitment but with less efficiency than AngII. Nevertheless, TRV023 and TRV027 provoke receptor internalization more efficiently than AngII and promote ERK, Src, and endothelial nitric oxide synthase phosphorylation in a b-arrestin-dependent manner. 170 These compounds have cardiovascular benefits of reducing blood pressure and promoting cardiac contraction. Thus, they provide an alternative for angiotensin-converting enzyme inhibitors and angiotensin receptor blockers which, despite their vasodilative effects, are contraindicated in acute heart failure as they may induce hypotension and decrease cardiac performance. 170 Functional selectivity has recently been investigated in natural renin-angiotensin-aldosterone system peptides which include AngII, AngIII, AngIV, and Ang- (1-7) . 171 Interestingly, Ang-(1-7) presents b-arrestin-biased agonism and acts as a competitive antagonist for AngII as it fails to stimulate G protein signaling. Ang-(1-7) also negatively regulates vasoconstriction in vivo as its binding to the AT 1 R attenuates phenylephrine-induced aorta contraction. bAR b 1 AR is the dominant bAR in the heart, which promotes catecholamine-induced cardiac inotropy, lusitropy, and chronotropy, and represents 75%-80% of the total cardiac bARs. However, b 2 AR expression contributes 20%-25% of the total cardiac bARs in normal hearts. 172 In failing human hearts, b 1 ARs are substantially downregulated, whereas b 2 AR levels remain unaltered. 173, 174 Chronic induction of G protein signaling through the b 1 AR promotes harmful apoptotic signaling, whereas b 2 AR activation in failing hearts promotes cell survival. 175 However, b-arrestin isoforms may regulate cardiac function and bAR-induced cardiac contractility differentially. Although barrestin1 seems to be mainly responsible for bAR desensitization, b-arrestin2 is cardioprotective with beneficial effects on b 1 AR-dependent contractility. 29, 176, 177 bAR-signaling through b-arrestin-dependent mechanism is induced by carvedilol, a nonselective bAR antagonist that also blocks a 1 -adrenergic receptors. Carvedilol is more effective than most traditional b-blockers in reducing mortality and morbidity of patients with congestive heart failure as it presents additional cardiovascular benefits associated with its antioxidative, anti-inflammatory, and antiproliferative properties. 178 While both carvedilol and the b-blocker propranolol act as inverse agonists for G sdependent adenylyl cyclase activation by the b 2 AR, only carvedilol activates ERK signaling in a b-arrestindependent manner. 49, 179 Carvedilol-induced effects are insensitive to pertussis toxin pretreatment and hence are independent of b 2 AR coupling to G i . 179, 180 Carvedilol induces EGFR transactivation by the b 1 AR in a GRK5/6 and barrestin-dependent manner. 89, 181 b-arrestins recruit the tyrosine-protein kinase Src to carvedilol-activated b 1 AR, promoting membrane-bound MMP activation, heparinbinding EGF cleavage, and release into the extracellular space for EGFR binding, resulting in EGFR tyrosine phosphorylation, EGFR internalization, and subsequent ERK signaling. b-arrestin-mediated b 1 AR transactivation of EGFR is cardioprotective in mice, highlighting the therapeutic benefits of carvedilol. 89 b 1 AR activation by carvedilol also promotes miRNA maturation in a b-arrestin-dependent fashion. 182 miRNAs are small noncoding RNAs that regulate posttranscriptional gene expression bearing a variety of effects on cardiac physiology and function. Irregularities in their expression are associated with myocardial infarction, hypertrophy, and cardiac remodeling. As a result, miRNAs are emerging as biomarkers and therapeutic targets for cardiovascular diseases and heart failure. 183, 184 Carvedilol upregulates a subset of mature and pre-miRNAs that includes miRNAs 125a-5p, 125b-5p, 150, 190, 199a-3p , and 214. 182, 185 Among them, miRNA-150 has cardioprotective effects and is downregulated during acute myocardial infarction, atrial fibrillation, dilated cardiomyopathy, ischemic injury, and heart failure. [185] [186] [187] [188] [189] [190] miRNA-199a-3p and miRNA-214 are activated by carvedilol in cardiomyocytes subjected to ischemia/reperfusion and promote cardiomyocyte survival by activating p-Akt survival signaling, inducing the expression SRY (sex determining region Y)-box 2 (Sox2), a transcription factor that promotes pluripotency and also by repressing the apoptosis-associated genes ddit4 (DNA damage-inducible transcript 4) and ing4 (inhibitor of growth family member 4). 191 blocks the effects of carvedilol on miRNA-190 expression. 182 b-arrestin's effects on miRNA maturation are attributed to its ability to interact with enzymes that regulate miRNA processing such as Drosha and hnRNPA1. 182 Recent studies have shown that pepducins, which are cell-permeable lipidated peptides representing the intracellular loop regions of GPCRs, can trigger signaling by acting as agonists or allosteric modulators although in general they act as inhibitors of GPCR activity. 192, 193 Of the various pepducins generated from the b 2 AR intracellular loop sequences, the pepducin called as ICL1-9 surprisingly elicits b-arrestinbiased signaling through the b 2 AR. 194 Like carvedilol, ICL1-9 promotes b 2 AR phosphorylation by GRKs, b-arrestin recruitment, receptor internalization, ERK activation, and EGFR transactivation. Nevertheless, unlike carvedilol, ICL1-9 does not block the orthosteric-binding site of b 2 AR and does not induce b 1 AR signaling and trafficking. Moreover, ICL1-9 also provokes cardiomyocyte contraction mediated by b-arrestin1. The b-arrestin-bias and inotropic abilities of ICL1-9 offer a new therapeutic option for cardiac dysfunction. 194 
D 2 R
Three b-arrestin-biased D 2 R ligands designated as UNC9975, UNC0006, and UNC9994 were identified from a small library of compounds generated based on the chemical structure of aripiprazole, which is a Food and Drug Administration-approved antipsychotic drug. 195 Aripiprazole was originally defined as a partial D 2 selective agonist, but later studies showed that based on the assay platform used, it had a wide range of efficacy (partial agonist, full agonist, and 
PTH1R
Biased ligands have been characterized for the PTH1R, a GPCR mainly expressed in kidneys and bones. PTH1R stimulation activates G protein and b-arrestin-mediated signaling pathways to regulate calcium homeostasis and/or bone formation. [197] [198] [199] Binding of conventional, nonselective agonist PTH(1-34) to PTH1R triggers G protein activation and also induces b-arrestin recruitment, resulting in receptor internalization and ERK signaling. However, b-arrestin-biased agonist, D-Trp(12),Tyr(34)-bPTH(7-34), antagonizes G protein coupling and triggers b-arrestin-mediated ERK activity and PTH1R internalization. These ligands also present distinct effects on bone formation. Although both PTH(1-34) and PTH(7-34) stimulate anabolic bone formation in mice, only PTH(1-34) increases markers of bone resorption and promotes hypercalcemia. 197 PTH(7-34)-triggered b-arrestin signaling, by its limiting effects on hypercalcemia, is a potential therapeutic target for the treatment of metabolic bone diseases like osteoporosis.
CONCLUSIONS
GPCRs are major therapeutic targets because their signal activation or inactivation affects almost all physiological pathways. b-arrestins are at the nexus of a variety of GPCR signal transduction modules and largely influence the signaling activities, vesicular trafficking, and fate of GPCRs by scaffolding a wide range of proteins to the activated receptor complex.
It has become evident that b-arrestin molecules embrace different activated conformations when they associate with the activated GPCR. 30, 32 These conformations of b-arrestins are dictated by ligand-triggered "barcoding" of the receptor tail by GRKs or by agonist-induced posttranslational modifications of b-arrestins. Biased agonists present an unmatched opportunity to selectively target one mode of signaling (through a G protein or b-arrestin); however, such compounds can have unique pharmacological and biological profiles than those observed when the particular signaling mode is stimulated by a "balanced" agonist. Therefore, to fully harness the potential benefits of biased agonism, it becomes critical to chart the signal transduction network(s) induced by the biased agonist in a cell-specific manner and further uncover the molecular mechanisms that regulate (or desensitize) biased signaling.
